Loading
A phase 2 trial of NGM120 Q4W in colorectal cancer, run by NGM Biopharmaceuticals, Inc, now recruiting.
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. is a phase 2 interventional study registered as NCT07033026 by NGM Biopharmaceuticals, Inc, with 136 participants planned, started 2025-06-25 and due to reach its primary completion in 2027-04. Interventions recorded: NGM120 Q4W, NGM120 Q8W and Placebo given.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/